Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Flaminia Pedretti
Observed names:
F. Pedretti,
Pedretti, Flaminia
Institutions:
Universitat Autònoma de Barcelona,
Vall d'Hebron Institute of Oncology
Observed institutions:
Universitat Autònoma de Barcelona,
Vall d'Hebron Institut de Recerca,
Vall d'Hebron Institute of Oncology,
Sapienza University of Rome
ORCID:
0009-0002-4855-6078
Observed ORCID:
0009-0002-4855-6078
OpenAlex ID:
A5033976911
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
2022
·
Benedetta Pellegrino
, Andrea Herencia-Ropero
, et al.
·
Cancer Research
·
109
PDF
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
2024
·
Andrea Herencia-Ropero
, Alba Llop-Guevara
, et al.
·
Genome Medicine
·
86
PDF
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
2021
·
Stefano Di Giulio
, Valeria Colicchia
, et al.
·
Oncogene
·
40
PDF
Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2025
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
·
Cancer Research
·
31
Interpretable inflammation landscape of circulating immune cells
2026
·
Laura Jiménez-Gracia
, Davide Maspero
, et al.
·
Nature Medicine
·
26
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
2025
·
Fabio Giuntini
, Íñigo González-Larreategui
, et al.
·
Cell Reports
·
6
PDF
SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors
2019
·
Marialaura Petroni
, Maria Sahùn Roncero
, et al.
·
Scientific Reports
·
4
PDF
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
2019
·
B. Pellegrino
, A. Llop-Guevara
, et al.
·
Annals of Oncology
·
3
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program
2026
·
Heura Domènech
, Sara Simonetti
, et al.
·
npj Precision Oncology
·
1
PDF
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts
2025
·
Andreu Òdena
, Laia Monserrat
, et al.
·
npj Precision Oncology
·
1
PDF
145P High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis
2021
·
B. Pellegrino
, A. Llop-Guevara
, et al.
·
Annals of Oncology
·
1
PDF
ISG15 promotes PARP inhibitor resistance in BRCA1-deficient cells by facilitating DNA replication and repair
2026
·
Rebecca A. Dagg
, Teressa Paulsen
, et al.
·
Nature Communications
PDF
Figure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Table S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S2 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S8 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S11 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Table S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Table S2 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S9 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Figure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
2026
·
Flaminia Pedretti
, Mohmed Abdalfttah
, et al.
Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer
2026
·
Laia Monserrat
, Judith García-García
, et al.
·
npj Breast Cancer
PDF
Show more works
View as search
Works count:
67
Citation count:
308
H-index:
6
I10-index:
5
Year
Topic
Type